# XTNT earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/XTNT) · [Earnings tab](https://www.lopjlb.com/stock/XTNT?tab=earnings)

Updated: 2026-08-03T01:32:59

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly updates XTNT evolved from a growth‑focused but margin‑constrained company in mid‑2024 to a cash‑generating, biologics‑centric business by mid‑2026. Revenue accelerated from $29.9 M in Q2 2024 to $133.9 M full‑year 2025 and $101‑105 M projected for 2026, driven by successive biologics launches, licensing inflows and the divestiture of non‑core hardware assets. Margin pressure eased as inventory write‑offs receded and gross margin is projected in the low‑60 % range for 2026 after a targeted 4‑5‑point recovery. The firm completed vertical integration of biologics, launched multiple DBM products, and secured a Dilon hemostatic license, while phasing out hardware through line rationalization and the Coflex/Paradigm sale. Commercial capabilities expanded with a larger sales force and new product introductions (nanOss Strata, CollagenX). However, recurring concerns include the impending loss of Q‑code licensing revenue, a high‑teens decline in hardware sales, seasonal headwinds, reliance on OEM partners, and potential margin hits from excess inventory. Debt was trimmed by $13.3 M in Q1 2026, reducing external capital needs.

## Latest CallCard · Q1

Xtant Medical raises 2026 revenue guidance to $101-105M after Dilon hemostatic license, Trivium Shaped launch, and Companion Spine divestiture; Q1 revenue $20.9M, gross margin 57.3%, debt reduced $13.3M.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlighted multiple milestones (Dilon lice

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Xtant Medical raises 2026 revenue guidance to $101-105M after Dilon hemostatic license, Trivium Shaped launch, and Companion Spine divestiture; Q1 revenue $20.9M, gross margin 57.3%, debt reduced $13.3M.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlighted multiple milestones (Dilon lice
- **2025 Q4:** Xtant Medical posted Q4 2025 revenue of $32.4M, full‑year $133.9M, generated positive cash flow, completed the Coflex divestiture, launched nanOss Strata and CollagenX, and guided 2026 revenue $95‑99M with low‑60s gross margin.
- **2025 Q3:** XTNT Q3: 19% revenue growth to $33.3M driven by $5.5M licensing; core biologics +4%; pending $19.2M asset sale to Companion Spine to close by year-end; 2025 guidance $131-135M reiterated; commercial rebuild underway.','tone':{'mgmt':0.3,'mgmt_rationale':'Management highlights achieved self-sustainab
- **2025 Q2:** Xtant Medical Q2 revenue $35.4M (+18% YoY) driven by biologics growth and $5M licensing; raised FY25 guidance to $131-135M; selling noncore Coflex/Paradigm OUS assets for $19.2M to focus on biologics and reduce debt.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'Management highlighted strong biologics g
- **2025 Q1:** Xtant Medical delivered 18% revenue growth to $32.9M in Q1 2025, achieved positive net income, completed vertical integration of biologics, launched new DBM products Trivium and FibreX, and raised full-year revenue guidance to $127-131M (8-11% growth) while citing CMS policy uncertainty.','tone': {'
- **2024 Q4:** XTNT posted record Q4 revenue of $31.5M and full-year $117.3M (28% YoY), achieved positive adjusted EBITDA of $438K despite a $1.5M inventory write-off, cut ~$5M in operating expenses since August, and guided 2025 revenue of $126-130M (8-11% growth) with mid-double-digit biologics growth, hardware f
- **2024 Q3:** XTNT reaffirms $116-120M FY24 guidance (27-31% growth) despite Q3 product delays; in-house biologics manufacturing and OEM deals drive margin expansion path to Q4 adj. EBITDA positivity. Licensing deal adds $1.5M upfront plus $3.75M minimum 2025 royalties. Cortera and OsteoVive Plus launches complet
- **2024 Q2:** XTNT Q2 revenue $29.9M (+48% YoY), reaffirms FY24 guidance $116-120M, expects positive operating cash flow Q4, stem cell internalization and amniotic launch driving margin improvement. Organic growth flat due to planned cannibalization; supply constraints on amniotic tissue and stem cell ramp timing

## Theme arcs

- **Revenue growth** (improving): From $29.9 M Q2 2024 to $133.9 M FY 2025 and $101‑105 M FY 2026 guidance
- **Margin improvement** (improving): Targeting low‑60% gross margin in 2026 after inventory‑related pressure
- **Biologics focus** (improving): Vertical integration, multiple launches and licensing boost biologics contribution
- **Hardware decline** (deteriorating): High‑teens revenue drop expected throughout 2026 as product lines are rationalized
- **Licensing revenue dynamics** (new): Initial $1.5 M upfront deal in 2024, but Q‑code license revenue slated to disappear in 2026
- **Debt reduction** (improving): Debt lowered by $13.3 M in Q1 2026, eliminating need for external capital
- **Commercial organization expansion** (improving): Sales force expansion and new product launches improve market visibility

## Fear persistence

- **License revenue loss** [recurring]: Q‑code license revenue expected to vanish in 2026
- **Hardware decline** [recurring]: High‑teens revenue drop projected throughout 2026
- **Seasonality** [recurring]: Quarter‑over‑quarter growth may be muted in Q3
- **OEM channel reliance** [recurring]: OEM/white‑label sales represent ~20% of biologics growth
- **Margin pressure** [recurring]: Inventory and excess/obsolete charges could offset margin gains

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/XTNT`